Published in final edited form as:

J Cardiovasc Electrophysiol. 2015 October ; 26(10): 1111–1116. doi:10.1111/jce.12768.

Efficacy of a Bio-absorbable Antibacterial Envelope to Prevent Cardiac Implantable Electronic Device Infections in High-Risk Subjects

Matthew J. Kolek, M.D., M.S.C.I.¹, Neel J. Patel, M.D.¹, Walter K. Clair, M.D., M.P.H.¹, S. Patrick Whalen, M.D.², Jeffrey N. Rottman, M.D.¹, Arvinth Kanagasundram, M.D.¹, Sharon T. Shen, M.D.¹, Pablo J. Saavedra, M.D.¹, Juan C. Estrada, M.D.¹, Robert L. Abraham, M.D.¹, and Christopher R. Ellis, M.D.¹

¹Department of Medicine, Cardiology Division, Vanderbilt University, 1211 Medical Center Drive, Nashville, Tennessee 37232

²Department of Medicine, Cardiology Division, Wake Forest University, Medical Center Boulevard, Winston-Salem, North Carolina 27157

Abstract

Introduction—Cardiac implantable electronic device (CIED) infections are potentially preventable complications associated with high morbidity, mortality, and cost. A recently developed bio-absorbable antibacterial envelope (TYRXTM-A) might prevent CIED infections in high-risk subjects. However, data regarding safety and efficacy have not been published.

Methods and results—In a single-center retrospective cohort study, we compared the prevalence of CIED infections among subjects with 2 risk factors treated with the TYRXTM-A envelope (N=135), the non-absorbable TYRXTM envelope (N=353), and controls who did not receive an envelope (N=636). Infection was ascertained by individual chart review. The mean (95% confidence interval) number of risk factors was 3.08 (2.84 to 3.32) for TYRXTM-A, 3.20 (3.07 to 3.34) for TYRXTM, and 3.09 (2.99 to 3.20) for controls, P=0.3. After a minimum 300 days follow-up, the prevalence of CIED infection was 0 (0%) for TYRXTM-A, 1 (0.3%) for TYRXTM, and 20 (3.1%) for controls (P=1 for TYRXTM-A versus TYRXTM, P=0.03 for TYRXTM-A versus controls, and P=0.002 for TYRXTM versus controls). In a propensity score-matched cohort of 316 recipients of either envelope and 316 controls, the prevalence of infection was 0 (0%) and 9 (2.8%), respectively, P=0.004. When limited to 122 TYRXTM-A recipients and 122 propensity-matched controls, the prevalence of CIED infections was 0 (0%) and 5 (4.1%), respectively, P=0.024.

Address for correspondence: Christopher R. Ellis, M.D., F.A.C.C., F.H.R.S., Assistant professor, Cardiac Electrophysiology, Vanderbilt Heart and Vascular Institute, 5414 Medical Center East, Nashville, TN 37232-8802, Office-(615) 936-2523/Mobile-(615) 480-0829, Christopher.ellis@vanderbilt.edu.

Dr. Ellis reports consulting fees from Medtronic, <\$5000 annually, as well as serving as consultant/on advisory boards of Boston Scientific, Atricure & Sente Heart; and research funding to Vanderbilt University, significant, from Thoratec, Heart Ware, & Boston Scientific. Dr. Whalen is a past member of the Medtronic speaker's bureau. Other authors: No disclosures.

Conclusions—Among high-risk subjects, the TYRX™-A bio-absorbable envelope was associated with a very low prevalence of CIED related infections that was comparable to that seen with the non-absorbable envelope.

Keywords

Cardiac implantable electronic device; infection; antibacterial envelope

Introduction

Cardiac implantable electronic device (CIED) infections have emerged as important complications of CIED procedures. CIED infections can be exceedingly difficult to treat, usually necessitating complete CIED system removal, and are associated with increased morbidity, mortality, and healthcare costs.^{1–4} Perioperative strategies to prevent CIED infections are particularly important, since inoculation often occurs as a result of bacterial seeding of the operative site (incision, device pocket, capsule, and/or CIED components) at the time of device implantation.⁵

Among patients undergoing CIED procedures, the non-absorbable version of the TYRX™ antibacterial envelope has been associated with a low prevalence of CIED infections.^{6–9} A new bio-absorbable version of the envelope is now commercially available, but its efficacy at preventing CIED infections is unknown. We hypothesized that the bio-absorbable TYRX™-A antibacterial envelope is associated with a low prevalence of CIED infections, similar to what has been observed with the non-absorbable envelope. To test our hypothesis, we conducted a retrospective cohort study comparing the prevalence of CIED infections in subjects treated with the bio-absorbable envelope, the non-absorbable envelope, and control subjects who underwent a CIED procedure but did not receive an envelope.

Methods

Study subjects

All patients age ≥ 18 years who had an antibacterial envelope implanted at Vanderbilt University Medical Center based on our institutional guidelines for use (see below) were included in the study. Non-absorbable (TYRX™) envelope recipients underwent implantation between November 12, 2009 and June 20, 2014, whereas bio-absorbable (TYRX™-A) envelope recipients underwent implantation between October 11, 2012 and June 30, 2014. The control population included adult subjects with ≥ 2 risk factors for CIED infection who had a device implanted between June 24, 2005 and May 24, 2010 without an antibacterial envelope. Control subjects underwent their index CIED procedures prior to the widespread use of antibacterial envelopes at our institution. Controls were derived from the Vanderbilt University Medical Center Synthetic Derivative, a de-identified, time-shifted, and previously validated version of the electronic medical record.^{10,11} The study protocol was approved by Vanderbilt University's institutional review board and found to be exempt from requiring individual informed consent.

After the TYRX™ envelopes became commercially available, we developed institutional guidelines for their use in patients undergoing a CIED procedure who had 2 of the following previously-described risk factors for infection: diabetes mellitus (history of diabetes or use of glycemic control agents), chronic kidney disease (serum creatinine ≥ 1.5 mg/dL at the time of implantation), systemic anti-coagulation (heparin, warfarin, or a novel oral anticoagulant), chronic daily corticosteroid use, fever ≥ 100.5 F or leukocytosis $\geq 11,000$ WBC/ μ L 24 hours prior to implantation, prior documented CIED infection, ≥ 3 transvenous leads (3 lead cardiac resynchronization therapy [CRT] systems or ≥ 1 abandoned leads), pacemaker dependence, or early pocket reentry within 2 weeks of original implantation.

The control population was derived by conducting a multi-tiered search of the Vanderbilt University Medical Center Synthetic Derivative database. Subjects who had a CIED implanted prior to the routine use of the antibacterial envelope at our institution were selected by searching for the following Current Procedural Terminology codes: 33206, 33207, 33208, 33212, 33213, 33214, 33215, 33216, 33217, 33218, 33220, 33224, 33225, 33226, 33233, 33234, 33235, 33240, and 33249. The resulting patient records were queried for the presence of diabetes mellitus, chronic kidney disease, systemic anticoagulation, chronic corticosteroid use, fever, and leukocytosis, as defined above. The resulting records were manually reviewed for the remaining risk factors and for incident CIED infections.

Types of CIED procedures

The index CIED procedure was defined for all subjects by chart review. This included control subjects where Current Procedural Terminology codes were used for initial screening but individual chart review was used to definitively determine procedure type. Procedure types included implantation of a single chamber pacemaker, dual chamber pacemaker, single chamber implantable cardioverter-defibrillator (ICD), dual chamber ICD, CRT pacemaker, CRT defibrillator, generator exchange, and device or lead revision. All of the CIED procedures considered as the index procedure for this study were performed at Vanderbilt University Medical Center by board-certified electrophysiologists in a dedicated electrophysiology laboratory or operating room. Patients specifically referred to Vanderbilt University Medical Center for management of a CIED infection related to a device implanted outside our facility were excluded from analysis. All subjects in the antibacterial envelope and control cohorts received perioperative antibiotics 0–15 minutes prior to skin incision. Outpatients received 1 gm intravenous cefazolin, unless penicillin allergic, in which case 1 gm intravenous vancomycin was used. Due to the high prevalence of antibiotic resistance at our institution, vancomycin was used as the first line agent for inpatients. Antibacterial envelopes were utilized by 9 out of 10 implanting electrophysiologists at our institution.

Ascertainment and definition of study endpoints

CIED infection, the primary study endpoint, was defined as a local infection, or systemic infection (e.g., sepsis, bacteremia, or endocarditis), ascertained by individual chart review. When an infection was identified, charts were also reviewed to ascertain bacterial culture results, treatment, and outcome. Infected subjects were treated with complete CIED system

explantation whenever feasible and/or systemic antibiotics. All subjects were followed for a minimum of 300 days after the index procedure.

Data management and statistical analysis

All patient variables were ascertained retrospectively by chart review and entered into a secure REDCap database.¹² Group comparisons were made using nonparametric tests for continuous variables and Pearson chi-square test or Fisher's exact test for categorical variables, as appropriate. For the primary endpoint, CIED infection after a minimum of 300 days follow-up, Fisher's exact test was used to test the difference in prevalence between antibacterial envelope recipients and controls.

Given the large number of risk factors evaluated, the low number of CIED infections, and concerns about over-fitting, we were unable to use multivariable regression to adjust for individual CIED infection risk factors and other variables.¹³ Rather, a propensity score for implantation of the antibacterial envelope, without regard for the primary study outcome, was calculated and used to create propensity-matched cohorts and outliers in each treatment group without an available match were excluded from further analysis.^{14,15} The 1st propensity-matched cohort included recipients of either the bio-absorbable (TYRX™-A) or non-absorbable (TYRX™) envelope and matching controls. The 2nd propensity-matched cohort was limited to TYRX™-A recipients and matching controls. The variables used for propensity score matching included age, sex, type of device, diabetes mellitus, chronic kidney disease, systemic anticoagulation, chronic steroid use, 3 leads, pacemaker dependence, fever or leukocytosis at the time of implantation, generator change or device upgrade/revision, early pocket re-entry, previous CIED infection, and length of follow-up. In addition, we conducted a time to event analysis using Cox proportional-hazards regression that included the propensity score as a variable to adjust for confounders.

Statistical analysis, including propensity score matching, was performed using SPSS for Mac (v22, IBM Corporation, Armonk, New York).

Role of the manufacturer of the TYRX™-A and TYRX™ antibacterial envelopes

Medtronic Inc., the manufacturer of the TYRX™-A and TYRX™ antibacterial envelopes, did not play a role in the conception, planning, funding, conduct, or analysis of this investigator-initiated study. The authors independently made the decision to submit the study results for publication. A version of the manuscript was provided to Medtronic Inc. prior to final submission for publication to ensure appropriate use of terms and protection of intellectual property.

Results

The study cohort included 1124 subjects with at least 2 CIED infection risk factors who underwent a CIED procedure. Of these, 135 received the TYRX™-A, 353 received the original TYRX™ envelope, and 636 did not receive an antibacterial envelope. Baseline patient characteristics including CIED infection risk factors are presented in Table 1. The mean (95% confidence interval [CI]) number of risk factors was similar among the 3 groups: 3.08 (2.84 to 3.32) for TYRX™-A, 3.20 (3.07 to 3.34) for TYRX™, and 3.09 (2.99 to 3.20)

for controls, $P=0.3$. The median (bootstrap 95% CI) length of follow-up differed significantly between TYRXTM-A recipients, TYRXTM recipients, and controls: 421 (393 to 442) days, 649 (557 to 757) days, and 1082 (972 to 1176) days, respectively, $P<0.001$.

To address the significant differences in individual risk factors and length of follow-up between TYRXTM-A recipients, TYRXTM recipients, and controls, we performed propensity score matching. For the 1st propensity matched cohort, we matched antibacterial envelope recipients (TYRXTM-A or TYRXTM) with controls. This resulted in a well-matched cohort of 632 subjects (Table 2). We also matched recipients of the absorbable TYRXTM-A with controls, resulting in a well-matched cohort of 244 subjects (Table 3).

For the entire study cohort, the prevalence of CIED infection was significantly lower among antibacterial envelope recipients than in controls: 0 (0%) for TYRXTM-A, 1 (0.3%) for TYRXTM, and 20 (3.1%) for controls ($P=0.001$ for global comparison, $P=1$ for TYRXTM-A versus TYRXTM, $P=0.034$ for TYRXTM-A versus controls, $P=0.002$ for TYRXTM versus controls, and $P<0.001$ for any antibacterial envelope versus controls, Table 4). In a propensity score-matched cohort of 316 envelope recipients (either TYRXTM-A or TYRXTM) and 316 controls, the prevalence of infection was 0 (0%) and 9 (2.8%), respectively, $P=0.004$. When limited to 122 TYRXTM-A recipients and 122 propensity-matched controls, the prevalence of CIED infections was 0 (0%) and 5 (4.1%), respectively, $P=0.024$.

We also conducted Cox proportional-hazards regression analysis and constructed Kaplan-Meier curves for CIED-free survival in antibacterial envelope recipients and controls. After adjusting for propensity score, the hazard ratio (95% CI) for CIED infection for antibacterial envelope recipients, compared with controls, was 0.05 (0.006 to 0.397), $P=0.005$ (Figure 1).

In an exploratory analysis, we analyzed the risk of CIED infection after early pocket reentry (within 2 weeks). In our total cohort of 1124 patients, 76 had early pocket reentry [18 of 636 (2.8%) controls, 50 of 353 (14.2%) of non-absorbable envelope recipients, and 8 of 135 (5.9%) of bio-absorbable envelope recipients]. None of the subjects who had early pocket reentry suffered a CIED infection.

Time to presentation, culture results, and outcomes of the 21 subjects who suffered a CIED infection are presented in Table 5. Sixteen patients (76.2%) had positive blood cultures. Sixteen were treated with complete CIED system extraction. Three patients (14.3%) died within 6 months of CIED infection presentation.

Discussion

We found that in high-risk subjects with at least 2 CIED infection risk factors, the use of a new bio-absorbable antibacterial envelope (TYRXTM-A) was associated with a very low prevalence of CIED infections. The prevalence of CIED infections observed with the bio-absorbable TYRXTM-A envelope was similar to the prevalence observed with the older non-absorbable envelope and was considerably lower than in control subjects who harbored a similar number of risk factors but were not treated with an antibacterial envelope. Our findings are clinically important because they provide evidence for the efficacy of the new bio-absorbable TYRXTM-A antibacterial envelope for preventing CIED infections in

selected high-risk patients. Due to the high morbidity, mortality, and costs associated with CIED infections, prevention of these complications is critically important. Additionally, increased accountability for preventable device related complications mean U.S. hospitals may shoulder the burden of payment for costly extraction, CIED re-implantation, and treatment of CIED infection.

Most CIED infections are thought to occur as a result of bacterial seeding at the time of implantation.⁵ Accordingly, strategies to reduce the incidence of CIED infections have focused on keeping the implantation site sterile in the perioperative period and include intraoperative intravenous cefazolin,¹⁶ skin preparation with chlorhexidine-alcohol,¹⁷ intraoperative antibacterial wash solutions, and perioperative oral antibiotics.¹⁸ Despite these therapies, the incidence of CIED infections remains unacceptably high at 1–3%,^{1–3,19–23} and additional strategies to reduce the rate of infections are needed. The TYRX™-A antibacterial envelope might emerge as a first line prophylactic therapy for patients at high risk for CIED infections. Although efficacy data from randomized prospective studies of the antibacterial envelope are not yet available, several studies have found that the use of the non-absorbable envelope is associated with a low prevalence of CIED infection.^{6–8} A recent retrospective study found that the routine use of the non-absorbable envelope was not only associated with a significant reduction of CIED infections but was also cost-effective.⁹ In addition to confirming these findings, our study provides the first clinical efficacy data on infection rates comparing subjects treated with the TYRX™-A bio-absorbable antibacterial envelope, the non-absorbable antibacterial envelope, and matched high-risk control subjects who were not treated with an envelope.

Several important limitations should be considered when interpreting the results of our study. As with all retrospective, non-randomized studies, our study is prone to selection bias and unmeasured confounders. There were potentially important differences in the prevalence of CIED risk factors between antibacterial envelope recipients and controls. Potential reasons for this observation include differences in how cases and controls were selected and how data were extracted, the use of historical controls, selection bias, or other, unknown reasons. In addition, the follow-up period was significantly shorter for antibacterial envelope recipients, particularly those treated with the TYRX™-A, than for controls. Because of concerns about over-fitting a model with the low number of events ($n = 21$) in our cohort, we were unable to adjust for length of follow-up, individual risk factors, and other variables with multivariable regression. Because of the low number of events, we were unable to stratify for individual CIED infection risk factors or determine their relative impact on the primary outcome. We sought to overcome many of these limitations by utilizing propensity score matching. We found that our primary results were similar in the propensity-matched cohorts and in the entire, unmatched cohort. However, it should be noted that the use of propensity score matching could introduce bias and result in over- or under-estimation of the treatment effect.

Conclusions

Among high-risk subjects with at least 2 established risk factors for infection, the use of the TYRX™-A bio-absorbable envelope was associated with a very low prevalence (0%) of

CIED related infections that was comparable to that seen with the non-absorbable envelope. Randomized clinical trial data are needed to support more wide spread use of the antibacterial envelope.

Acknowledgments

This project was supported by Clinical and Translational Science Award No. **UL1TR000445** from the National Center for Advancing Translational Sciences. Its contents are solely the responsibility of the authors and do not necessarily represent official views of the National Center for Advancing Translational Sciences or the National Institutes of Health.

References

1. Voigt A, Shalaby A, Saba S. Rising rates of cardiac rhythm management device infections in the United States: 1996 through 2003. *J Am Coll Cardiol.* 2006; 48:586–597. [PubMed: 16875989]
2. Greenspon AJ, Patel JD, Lau E, Ochoa JA, Frisch DR, Ho RT, Pavri BB, Kurtz SM. 16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008. *J Am Coll Cardiol.* 2011; 58:1001–1006. [PubMed: 21867833]
3. de Bie MK, van Rees JB, Thijssen J, Borleffs CJW, Trines SA, Cannegieter SC, Schalij MJ, van Erven L. Cardiac device infections are associated with a significant mortality risk. *Heart Rhythm.* 2012; 9:494–498. [PubMed: 22056722]
4. Sohail MR, Hussain S, Le KY, Dib C, Lohse CM, Friedman PA, Hayes DL, Uslan DZ, Wilson WR, Steckelberg JM, Baddour LM. Risk factors associated with early- versus late-onset implantable cardioverter-defibrillator infections. *J Interv Card Electrophysiol.* 2011; 31:171–183. [PubMed: 21365264]
5. Da Costa A, Lelievre H, Kirkorian G, Celard M, Chevalier P, Vandenesch F, Etienne J, Touboul P. Role of the preaxillary flora in pacemaker infections: A prospective study. *Circulation.* 1998; 97:1791–1795. [PubMed: 9603533]
6. Kolek MJ, Dresen WF, Wells QS, Ellis CR. Use of an antibacterial envelope is associated with reduced cardiac implantable electronic device infections in high-risk patients. *Pacing Clin Electrophysiol.* 2012; 36:354–361. [PubMed: 23252988]
7. Bloom HL, Constantin L, Dan D, De Lurgio DB, El-Chami M, Ganz LI, Glead KJ, Hackett FK, Kanuru NK, Lerner DJ, Rasekh A, Simons GR, Sogade FO, Sohail MR, COoperative Multicenter study Monitoring a CIED ANtimicrobial Device Investigators. Implantation success and infection in cardiovascular implantable electronic device procedures utilizing an antibacterial envelope. *Pacing Clin Electrophysiol.* 2011; 34:133–142. [PubMed: 20942819]
8. Mittal S, Shaw RE, Michel K, Palekar R, Arshad A, Musat D, Preminger M, Sichrovsky T, Steinberg JS. Cardiac implantable electronic device infections: incidence, risk factors, and the effect of the AegisRx antibacterial envelope. *Heart Rhythm.* 2014; 11:595–601. [PubMed: 2433543]
9. Shariff N, Eby E, Adelstein E, Jain S, Shalaby A, Saba S, Wang NC, Schwartzman D. Health and economic outcomes associated with use of an antimicrobial envelope as a standard of care for cardiac implantable electronic device implantation. *J Cardiovasc Electrophysiol.* 2015; 26
10. Roden D, Pulley J, Basford M, Bernard G, Clayton E, Balser J, Masys D. Development of a large-scale de-identified DNA biobank to enable personalized medicine. *Clin Pharmacol Ther.* 2008; 84:362–369. [PubMed: 18500243]
11. Denny JC, Ritchie MD, Crawford DC, Schildcrout JS, Ramirez AH, Pulley JM, Basford MA, Masys DR, Haines JL, Roden DM. Identification of genomic predictors of atrioventricular conduction: using electronic medical records as a tool for genome science. *Circulation.* 2010; 122:2016–2021. [PubMed: 21041692]
12. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform.* 2009; 42:377–381. [PubMed: 18929686]

13. Courvoisier DS, Combescure C, Agoritsas T, Gayet-Ageron A, Perneger TV. Performance of logistic regression modeling: beyond the number of events per variable, the role of data structure. *J Clin Epidemiol*. 2011; 64:993–1000. [PubMed: 21411281]
14. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. *Am J Epidemiol*. 1999; 150:327–333. [PubMed: 10453808]
15. Gum PA, Thamilarasan M, Watanabe J, Blackstone EH, Lauer MS. Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease. *JAMA*. 2001; 286:1187–1194. [PubMed: 11559263]
16. de Oliveira JC, Martinelli M, Nishioka SA, Varejão T, Uipe D, Pedrosa AA, Costa R, Danik SB. Efficacy of antibiotic prophylaxis before the implantation of pacemakers and cardioverter-defibrillators. *Circ Arrhythm Electrophysiol*. 2009; 2:29–34. [PubMed: 19808441]
17. Darouiche RO, Wall MJ Jr, Itani KM, Otterson MF, Webb AL, Carrick MM, Miller HJ, Awad SS, Crosby CT, Mosier MC, AlSharif A, Berger DH. Chlorhexidine-alcohol versus povidone-iodine for surgical-site antisepsis. *New Engl J Med*. 2010; 362:18–26. [PubMed: 20054046]
18. Kolek MJ, Ellis CR. New approaches to decrease cardiac implantable electronic device infections. *Cardiac Electrophysiology Clinics*. 2014; 6:279–284.
19. Sohail MR, Henrikson CA, Braid-Forbes MJ, Forbes KF, Lerner DJ. Comparison of mortality in women versus men with infections involving cardiovascular implantable electronic device. *Am J Cardiol*. 2013; 112:1403–1409. [PubMed: 23972346]
20. Lekkerkerker JC, van Nieuwkoop C, Trines SA, van der Bom JG, Bernardis A, van de Velde ET, Bootsma M, Zeppenfeld K, Jukema JW, Borleffs J-W, Schalij MJ, van Erven L. Risk factors and time delay associated with cardiac device infections: Leiden device registry. *Heart*. 2009; 95:715–720. [PubMed: 19036758]
21. Dasgupta A, Montalvo J, Medendorp S, Lloyd-Jones DM, Ghossein C, Goldberger J, Passman R. Increased complication rates of cardiac rhythm management devices in ESRD patients. *Am J Kidney Dis*. 2007; 49:656–663. [PubMed: 17472848]
22. Gould PA, Krahn AD, Canadian Heart Rhythm Society Working Group on Device Advisories. Complications associated with implantable cardioverter-defibrillator replacement in response to device advisories. *JAMA*. 2006; 295:1907–1911. [PubMed: 16639049]
23. Bloom H, Heeke B, Leon A, Mera F, Delurgio D, Beshai J, Langberg J. Renal insufficiency and the risk of infection from pacemaker or defibrillator surgery. *Pacing Clin Electrophysiol*. 2006; 29:142–145. [PubMed: 16492298]

Number at risk				
Envelope				
488	302	160	110	45
No envelope				
636	434	375	308	180

Figure 1.
Probability of cardiac implantable electronic device infection-free survival among subjects with 2 risk factors for infection who did (blue curve) and did not (black curve) receive an antibacterial envelope.

Table 1

Clinical characteristics for the entire study cohort.

	Bio-absorbable envelope recipients (N=135)	Non-absorbable envelope recipients (N=353)	Controls (N=636)	P-value*
Age, years, median (95% CI)	67 (63.5 to 70.5)	69 (67 to 71)	70 (68 to 71)	0.059
Women	43 (31.9%)	111 (31.4%)	236 (37.1%)	0.153
Serum creatinine, median, mg/dL (95% CI)	1.28 (1.15 to 1.39)	1.23 (1.15 to 1.29)	1.31 (1.27 to 1.36)	0.124
Chronic kidney disease	43 (31.9%)	121 (34.3%)	296 (46.5%)	<0.001
Diabetes mellitus	55 (40.7%)	148 (41.9%)	344 (54.1%)	<0.001
Systemic anticoagulation	77 (57%)	204 (57.8%)	433 (68.1%)	0.001
Chronic corticosteroids	9 (6.7%)	28 (7.9%)	92 (14.5%)	0.001
Prior CIED infection	4 (3%)	27 (7.6%)	25 (3.9%)	0.019
Pacemaker dependent	48 (35.6%)	109 (30.9%)	198 (31.1%)	0.569
Fever/leukocytosis	14 (10.4%)	56 (15.9%)	178 (28%)	<0.001
Generator change/upgrade	90 (66.7%)	180 (51%)	215 (33.8%)	<0.001
3 or more leads	68 (50.4%)	208 (58.9%)	168 (26.4%)	<0.001
Early pocket reentry	8 (5.9%)	50 (14.2%)	18 (2.8%)	<0.001

CI: confidence interval; CIED: cardiac implantable electronic device.

*
P-values from Kruskal-Wallis test for continuous variables and Pearson chi-square for discrete variables.

Table 2

Clinical characteristics for antibacterial envelope (TYRX™-A or TYRX™) recipients and propensity score-matched controls.

	<u>Antibacterial envelope recipients (N=316)</u>	<u>Controls (N=316)</u>	<u>P-value</u> [*]
Absorbable envelope	76 (24.1%)	0	--
Age, years, median (95% CI)	70 (68 to 71)	70 (68 to 72)	0.925
Women	101 (32%)	116 (36.7%)	0.209
Serum creatinine, median, mg/dL (95% CI)	1.36 (1.26 to 1.44)	1.28 (1.21 to 1.34)	0.250
Chronic kidney disease	136 (43%)	133 (42.1%)	0.809
Diabetes mellitus	150 (47.5%)	143 (45.3%)	0.577
Systemic anticoagulation	204 (64.6%)	202 (63.9%)	0.868
Chronic corticosteroids	32 (10.1%)	40 (12.7%)	0.317
Prior CIED infection	19 (6%)	16 (5.1%)	0.602
Pacemaker dependent	103 (32.6%)	91 (28.8%)	0.301
Fever/leukocytosis	63 (19.9%)	71 (22.5%)	0.436
Generator change/upgrade	151 (47.8%)	144 (45.6%)	0.577
3 or more leads	150 (47.5%)	133 (42.1%)	0.174
Early pocket reentry	15 (4.7%)	17 (5.4%)	0.717
Length of follow-up, days, median (95% CI)	569 (524 to 640)	559 (435 to 768)	0.073

CI: confidence interval; CIED: cardiac implantable electronic device.

* P-values from Mann-Whitney U test for continuous variables and Pearson chi-square or Fisher's exact test, as appropriate, for discrete variables.

Table 3

Clinical characteristics for TYRX™-A absorbable envelope recipients and propensity score-matched controls.

	TYRX™-A recipients (N=122)	Controls (N=122)	P-value*
Age, years, median (95% CI)	68 (65 to 71)	69 (66 to 72.5)	0.454
Women	39 (32%)	47 (38.5%)	0.284
Serum creatinine, median, mg/dL (95% CI)	1.30 (1.19 to 1.45)	1.19 (1.11 to 1.31)	0.434
Chronic kidney disease	43 (35.2%)	45 (36.9%)	0.790
Diabetes mellitus	52 (42.6%)	59 (48.4%)	0.368
Systemic anticoagulation	75 (61.5%)	67 (54.9%)	0.299
Chronic corticosteroids	9 (7.4%)	14 (11.5%)	0.273
Prior CIED infection	4 (3.3%)	2 (1.6%)	0.408
Pacemaker dependent	42 (34.4%)	41 (33.6%)	0.893
Fever/leukocytosis	13 (10.7%)	18 (14.8%)	0.336
Generator change/upgrade	77 (63.1%)	77 (63.1%)	1
3 or more leads	58 (47.5%)	54 (44.3%)	0.607
Early pocket reentry	7 (5.7%)	5 (4.1%)	0.554
Length of follow-up, days, median (95% CI)	412 (371.5 to 432)	230 (149 to 326)	0.001

CI: confidence interval; CIED: cardiac implantable electronic device.

* P-values from Mann-Whitney U test for continuous variables and Pearson chi-square or Fisher's exact test, as appropriate, for discrete variables.

Table 4

Frequency of cardiac implantable electronic device infections among antibacterial envelope recipients and controls in the entire study cohort and in the propensity score-matched cohorts.

	<u>TYRXTM-A</u>	<u>TYRXTM</u>	<u>Controls</u>	<u>P-value</u> [*]
Entire study cohort (N=1124)	0	1 (0.3%)	20 (3.1%)	0.001
Propensity-matched cohort 1 (N=632)	0	0	9 (2.8%)	0.004
Propensity-matched cohort 2 (N=244)	0	--	5 (4.1%)	0.024

* P-values from Fisher's exact test. Propensity-matched cohort 1 includes TYRXTM-A and TYRXTM recipients and matching controls. Propensity-matched cohort 2 includes TYRXTM-A recipients and matching controls.

Table 5

Clinical presentation, treatment, and outcomes of subjects who had a cardiac implantable electronic device infection.

Days until infection, median (95% confidence interval)	107 (48 to 297)
Time until infection, n (%)	
< 6 months	13 (61.9%)
6 to 12 months	4 (19%)
>12 months	4 (19%)
Infection type, n (%)	
Pocket only	6 (28.6%)
Systemic	15 (71.4%)
Blood culture results, n (%)	
CoNS	4 (19%)
MSSA	3 (14.3%)
MRSA	3 (14.3%)
Enterococcus	3 (14.3%)
Streptococcus	2 (9.5%)
Pseudomonas	1 (4.8%)
Negative	5 (23.8%)
CIED system extraction, n (%)	16 (76.2%)
Died within 6 months of infection, n (%)	3 (14.3%)

CIED: cardiac implantable electronic device; CoNS: coagulase-negative Staphylococcus; MRSA: methicillin-resistant Staphylococcus aureus; MSSA: methicillin-sensitive Staphylococcus aureus.